Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.37 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21166986 | 0.81 | ITGB3 (0.41) | KMT2AMEN1APLNRITGB1ITGA4 | |
| SCHEMBL21339799 | 0.81 | GLP1R (0.44) | KMT2AMEN1ALDH1A1HPGDGLP1R | |
| SCHEMBL22479117 | 0.79 | ACE (0.33) | MMP1MMP3KMT2AMEN1ITGB1 | |
| SCHEMBL21349175 | 0.77 | ITGB1 (0.46) | MMP1MMP3APLNRITGB1ITGA4 | |
| SCHEMBL21350659 | 0.76 | MMP1 (0.32) | MMP1MMP3KMT2AMEN1ITGB3 | |
| SCHEMBL24140122 | 0.75 | ITGB1 (0.44) | MMP1MMP3APLNRITGB1ITGA4 | |
| SCHEMBL21166987 | 0.75 | ITGB3 (0.41) | KMT2AMEN1APLNRITGB1ITGA4 | |
| SCHEMBL30391539 | 0.75 | CMA1 (0.43) | MMP1MMP3KMT2AMEN1ITGB3 | |
| SCHEMBL21167022 | 0.75 | APLNR (0.46) | MMP1MMP3APLNRITGB1ITGA4 | |
| SCHEMBL21339759 | 0.75 | MMP3 (0.54) | MMP1MMP3KMT2AITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | ADOCIA (FR) | 2023-04-25 | — | — | US | disclosed |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2022-12-29 | — | — | US | disclosed |
| US-11173109-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | ADOCIA (FR) | 2021-11-16 | — | — | US | disclosed |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2021-04-27 | — | — | US | disclosed |
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633460-B2 | Injectable solution at pH 7 comprising at least one basal insulin wherein the pI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals | IAPP, HBB, IGF1R | MMP1 301/4885MMP3 2113/4885KMT2A 3929/4885 |
| US-20190275156-A1 | COMPOSITIONS SOUS FORME D'UNE SOLUTION AQUEUSE INJECTABLE COMPRENANT DU GLUCAGON HUMAIN ET UN CO-POLYAMINOACIDE | GCG, GLP1R, GHSR | MMP1 2515/4885MMP3 1731/4885KMT2A 3731/4885 |
| US-20190274954-A1 | Copositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | IAPP, GLP1R, INSR | MMP1 1809/4885MMP3 3476/4885KMT2A 4797/4885 |
| US-20220409523-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG AND A CO-POLYAMINO ACID | IAPP, INSR, GLP1R | MMP1 1888/4885MMP3 3639/4885KMT2A 4716/4885 |
| US-10987426-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GLP1R, GCGR | MMP1 1887/4885MMP3 2378/4885KMT2A 1912/4885 |
| US-11173109-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid | IAPP, INSR, GLP1R | MMP1 2036/4885MMP3 3610/4885KMT2A 4745/4885 |
| US-20190275115-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHEREIN THE PI IS COMPRISED FORM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, GCG, HBB | MMP1 437/4885MMP3 2290/4885KMT2A 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.